SummaryRMgm-5265
|
||||||||
*RMgm-5265| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene tagging |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 36625655 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Wichers-Misterek JS, Gilberger TW |
| Name Group/Department | Centre for Structural Systems Biology |
| Name Institute | Centre for Structural Systems Biology |
| City | Hamburg |
| Country | Germany |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-5265 |
| Principal name | PbSPM3-GFP |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | PbSPM3-GFP expression in oocysts and sporozoites. In sporozoites, the fluorescent signal extended from the apical end towards the rear around the nucleus. |
| Sporozoite | PbSPM3-GFP expression in oocysts and sporozoites. In sporozoites, the fluorescent signal extended from the apical end towards the rear around the nucleus. |
| Liver stage | Not different from wild type |
| Additional remarks phenotype | Mutant/mutation Protein (function) Phenotype For P. falciparum SPM3 evidence is presented that: Other mutants |
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1342500 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1327300 | ||||||||||||||||||||||||||
| Gene product | conserved Plasmodium protein, unknown function | ||||||||||||||||||||||||||
| Gene product: Alternative name | SPM3 | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | GFP | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | |||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | For endogenous tagging of PbSPM3 (PBANKA_1342500), a 992 bp long 3’ homology region was amplified from PbANKA wild-type genomic DNA. The reverse primer encoded the same linker sequence that was used for GFP-tagging of PfSPM3 as described in Birnbaum et al. 2017. The amplicon was cloned into the pL18 489 vector using EcoRI/BamHI restriction sites. Prior to transfection, the vector was linearized using the SwaI restriction enzyme followed by ethanol-precipitation | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||